Merck’s Keytruda demonstrates adjuvant use in kidney cancer

The interim analysis carried out by an independent data monitoring committee, revealed Keytruda showed a statistically significant and clinically meaningfully improvement in disease free survival compared with placebo. The trial will continue to evaluate overall survival, a key secondary endpoint. The safety profile of Keytruda in the trial was consistent with that observed in previously reported studies, Merck said.
Read more...

;